Radiation Therapy
Treatment for Non Melanoma Skin Cancer Squamous Cell Carcinoma
Typical Dosage: 60-70 Gy in 30-35 fractions
Effectiveness
90%
Safety Score
25%
Clinical Trials
30
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
60-70 Gy in 30-35 fractions
Time to Effect
4-8 weeks
Treatment Duration
3-7 weeks
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$500
Side Effect Mgmt:$300
Total Annual:$15,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$17,174
Cost per Remission
$17,174
Comparison vs Surgical Excision
Cost Difference
+$13,000/year
More expensive
QALY Difference
-0.10 QALYs
Worse outcomes
Dominance
No dominance
Radiation Therapy Outcomes
for Non Melanoma Skin Cancer Squamous Cell Carcinoma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+92%
Remission Rate
+92%
Common Side Effects
Skin redness/irritation (radiation dermatitis)
+90%
Fatigue
+60%
Pain/soreness
+40%
Hair loss (in treated area)
+100%
Ulceration
+7%
Long-term scarring/pigment changes
+60%
Sources:
Active Clinical Trials
10 active trials recruiting for Radiation Therapy in Non Melanoma Skin Cancer Squamous Cell Carcinoma
Skin Cancer and Hyperthermia and Radiotherapy
NCT06384053RECRUITINGNA
100 participants
INTERVENTIONAL
Aarau, Switzerland +3 more
Started: Jan 1, 2025
Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
NCT06782399NOT YET RECRUITINGEARLY_PHASE1
25 participants
INTERVENTIONAL
Started: Jul 1, 2025
CivaDerm(TM) Surface Therapy Pilot Study
NCT04480645RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Morrisville, United States
Started: May 1, 2024
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
NCT07311057ENROLLING BY INVITATIONPHASE3
20 participants
INTERVENTIONAL
Mashhad, Iran
Started: Dec 20, 2025
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
NCT03474497RECRUITINGPHASE1, PHASE2
45 participants
INTERVENTIONAL
Sacramento, United States +1 more
Started: May 20, 2019
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
NCT05574101ACTIVE NOT RECRUITINGPHASE2
34 participants
INTERVENTIONAL
Aurora, United States +12 more
Started: Oct 6, 2022
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
NCT05229614RECRUITINGPHASE2
27 participants
INTERVENTIONAL
Darmstadt, Germany +3 more
Started: Jul 26, 2022
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
NCT06606028RECRUITING
250 participants
OBSERVATIONAL
San Francisco, United States
Started: Oct 9, 2024
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
NCT04892849RECRUITING
200 participants
OBSERVATIONAL
Erlangen, Germany
Started: Apr 30, 2021
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT05837767RECRUITINGNA
26 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Jul 24, 2023
Completed Clinical Trials
4 completed trials for Radiation Therapy in Non Melanoma Skin Cancer Squamous Cell Carcinoma
Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)
NCT03353077COMPLETEDNA
28 participants
INTERVENTIONAL
Meldola, Italy
Started: Nov 21, 2017
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
NCT00126555COMPLETEDPHASE2
23 participants
INTERVENTIONAL
Houston, United States
Started: Mar 1, 2005
Electronic Brachytherapy for the Treatment of NMSC
NCT01016899COMPLETED
187 participants
OBSERVATIONAL
Tuscaloosa, United States +4 more
Started: Aug 1, 2009
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
NCT02318771COMPLETEDPHASE1
41 participants
INTERVENTIONAL
Philadelphia, United States
Started: Feb 5, 2015
Showing 20 of 32 total trials